Directory › Piramal Pharma Solutions

Piramal Pharma Solutions — Grangemouth

Grangemouth, United Kingdom · CDMO

This is a record of what regulators published, not a rating.

Site facts

Company
Piramal Pharma Solutions
Name(s) in FDA data
Piramal Healthcare UK Ltd.
FEI number(s)
3003723155 (present in FDA Data Dashboard records for this name and city)
Location (as in FDA data)
Grangemouth, United Kingdom
Records matched
3 FDA inspections
Most recent FDA inspection in dataset
18 Mar 2022 — VAI

Capabilities (from the company's website)

  • Sterile fill-finish
    …ated services provided include development and manufacturing of payload-linker, mAbs, and fill-finish. Manufacturing Expertise Our vast experience with different types of cytotoxic payloads s…
  • Small molecule
    …f the art analytical laboratories provide a wide array of analytical methods ranging from small molecule analysis to cell killing assays and ELISA development ADCelerate: Integrated Solutions ex…
  • Highly potent (HPAPI)
    …timization and Scale-up We have experience in the development of major ADC platforms, non-cytotoxics, and a broad range of protein conjugates. We offer expertise in preclinical proof-of-con…
  • ADCs & bioconjugates
    …s ( 25 min) Glasgow Airport (GLA), Paisley, Scotland Driving Distance: 37 miles ( 45 min) Antibody Drug Conjugate and Bioconjugate Services Piramal's Grangemouth facility offers development, clinical and…
  • Clinical trial supply & packaging
    …ate , is an integrated ADC solution that accelerates timelines for developing the initial clinical supply of both drug substance and drug product Why Partner with Us? Domain Leadership Building…
  • Analytical testing
    …es including Antibody Drug Conjugates (ADCs) since 2004. The site provides full process & analytical development services to support proof-of-concept & toxicology studies with commercial manufacturing o…
  • Formulation & process development
    …e IND-enabling studies Preclinical Development and Proof-of-Concept Studies arrow_outward Process Development, Optimization and Scale-up We have experience in the development of major ADC platforms,…

Taken from the company's web page for this site. Source: https://www.piramalpharmasolutions.com/facilities/antibody-drug-conjugate-development-and-manufacturing-grangemouth, checked 16 Oct 2026. Quoted text shows the wording each tag is based on.

Regulatory timeline

Newest first. Each entry links to the published source. Inspection classifications: NAI = no action indicated, VAI = voluntary action indicated, OAI = official action indicated (FDA definitions). Posted 483 citations are FDA's short summaries, not the full Form 483.

  1. 18 Mar 2022
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3003723155, inspection ID 1190348)

  2. 30 Jan 2015
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3003723155, inspection ID 923780)

  3. 24 Jun 2013
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3003723155, inspection ID 840810)

This is a record of what regulators published, not a rating. Absence of a record here does not mean no record exists; see methodology for what we check and how records are matched.